The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
JSKN027 will become the first ADC with this mechanism to enter human trials.
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
A binary Xpovio catalyst is set for March.
BeOne terminates a MUC1-targeting project.
Welireg, Padcev, and a surprise fillip for Flare.
Two new pivotal Chinese first-line trials have started in lung cancer.
